{"id":2259,"date":"2023-06-25T17:55:01","date_gmt":"2023-06-25T17:55:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/trifluoperazine\/"},"modified":"2023-06-25T18:04:38","modified_gmt":"2023-06-25T18:04:38","slug":"trifluoperazine","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/trifluoperazine\/","title":{"rendered":"Trifluoperazine"},"content":{"rendered":"

<\/p>\n

CLINICAL USE<\/h3>\n

Schizophrenia and other psychoses Anxiety Severe nausea and vomiting<\/p>\n

DOSE IN NORMAL RENAL FUNCTION<\/h3>\n

Schizophrenia: initially 5 mg twice daily, increased by 5 mg after 1 week, then at intervals of 3 days according to response Anxiolytic and anti-emetic: 2\u20134 mg daily in divided doses; maximum 6 mg<\/p>\n

PHARMACOKINETICS<\/h3>\n
  • Molecular weight                           : 407.5<\/li>\n
  • %Protein binding                           : >99<\/li>\n
  • %Excreted unchanged in urine     : <1<\/li>\n
  • Volume of distribution (L\/kg)       : 160<\/li>\n
  • half-life \u2013 normal\/ESRD (hrs)      : 22\/\u2013
    \n

    DOSE IN RENAL IMPAIRMENT<\/h3>\n

    GFR (mL\/MIN)<\/h4>\n<\/li>\n
  • 20 to 50     : Dose as in normal renal function. Start with low dose<\/li>\n
  • 10 to 20     : Dose as in normal renal function. Start with low dose<\/li>\n
  • <10           : Dose as in normal renal function. Start with low dose
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n
  • CAPD                : Not dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HD                     : Not dialysed. Dose as in GFR <10 mL\/min<\/li>\n
  • HDF\/high flux   : Unknown dialysability. Dose as in GFR <10 mL\/min<\/li>\n
  • CAV\/VVHD      : Unlikely to be dialysed. Dose as in GFR 10 to 20 mL\/min
    \n

    IMPORTANT DRUG INTERACTIONS<\/h3>\n

    Potentially hazardous interactions with other drugs<\/li>\n

  • Anaesthetics: enhanced hypotensive effect<\/li>\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids<\/li>\n
  • Anti-arrhythmics: increased risk of ventricular arrhythmias with anti- arrhythmics that prolong the QT interval, e.g. procainamide, disopyramide and amiodarone \u2013 avoid concomitant use with amiodarone<\/li>\n
  • Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin \u2013 avoid concomitant use<\/li>\n
  • Antidepressants: increased level of tricyclics; possibly increased risk of antimuscarinic side effects<\/li>\n
  • Anti-epileptics: antagonism (convulsive threshold lowered)<\/li>\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine<\/li>\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use<\/li>\n
  • Antivirals: concentration possibly increased with ritonavir Anxiolytics and hypnotics: increased sedative effects<\/li>\n
  • Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol<\/li>\n
  • Diuretics: enhanced hypotensive effect<\/li>\n
  • Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity<\/li>\n
  • Pentamidine: increased risk of ventricular arrhythmias<\/li>\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant use
    \n

    ADMINISTRATION<\/h3>\n

    Reconstition<\/h4>\n

    \u2013<\/p>\n

    Route<\/h4>\n

    Oral<\/p>\n

    Rate of Administration<\/h4>\n

    \u2013<\/p>\n

    Comments<\/h4>\n

    \u2013<\/p>\n

    OTHER INFORMATION<\/h4>\n

    Reduce starting dose in elderly or frail patients by at least half .<\/li>\n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Schizophrenia and other psychoses Anxiety Severe nausea and<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-2259","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=2259"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2259\/revisions"}],"predecessor-version":[{"id":2326,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2259\/revisions\/2326"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=2259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=2259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=2259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}